XVIVOS logo

Xvivo Perfusion BATS-CHIXE:XVIVOS Stock Report

Last Price

SEK 448.75

Market Cap

SEK 14.2b

7D

-10.9%

1Y

n/a

Updated

04 Nov, 2024

Data

Company Financials +

Xvivo Perfusion AB (publ)

BATS-CHIXE:XVIVOS Stock Report

Market Cap: SEK 14.2b

XVIVOS Stock Overview

A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania.

XVIVOS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Xvivo Perfusion AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xvivo Perfusion
Historical stock prices
Current Share PriceSEK 448.75
52 Week HighSEK 503.50
52 Week LowSEK 448.75
Beta2.1
11 Month Change-10.87%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Change169.36%
Change since IPO160.14%

Recent News & Updates

Recent updates

Shareholder Returns

XVIVOSGB Medical EquipmentGB Market
7D-10.9%-8.3%-1.2%
1Yn/a-1.7%8.9%

Return vs Industry: Insufficient data to determine how XVIVOS performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how XVIVOS performed against the UK Market.

Price Volatility

Is XVIVOS's price volatile compared to industry and market?
XVIVOS volatility
XVIVOS Average Weekly Movementn/a
Medical Equipment Industry Average Movement5.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: XVIVOS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine XVIVOS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998161Christoffer Rosenbladwww.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.

Xvivo Perfusion AB (publ) Fundamentals Summary

How do Xvivo Perfusion's earnings and revenue compare to its market cap?
XVIVOS fundamental statistics
Market capSEK 14.19b
Earnings (TTM)SEK 204.27m
Revenue (TTM)SEK 750.59m

69.5x

P/E Ratio

18.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XVIVOS income statement (TTM)
RevenueSEK 750.59m
Cost of RevenueSEK 192.08m
Gross ProfitSEK 558.52m
Other ExpensesSEK 354.25m
EarningsSEK 204.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)6.48
Gross Margin74.41%
Net Profit Margin27.21%
Debt/Equity Ratio0%

How did XVIVOS perform over the long term?

See historical performance and comparison